Einav Liran, Finkelstein Amy, Polyakova Maria
Department of Economics, Stanford University, and NBER, 579 Serra Mall, Stanford, CA 94305- 6072.
Department of Economics, Massachusetts Institute of Technology, and NBER, 77 Massachusetts Avenue, Building E52, Room 442, Cambridge MA 02139.
Am Econ J Econ Policy. 2018 Aug;10(3):122-153. doi: 10.1257/pol.20160355.
We explore how private drug plans set cost-sharing in the context of Medicare Part D. While publicly-provided drug coverage typically involves uniform cost-sharing across drugs, we document substantial heterogeneity in the cost-sharing for different drugs within privately-provided plans. We also document that private plans systematically set higher consumer cost sharing for drugs or classes associated with more elastic demand; to do so we estimate price elasticities of demand across more than 150 drugs and across more than 100 therapeutic classes. We conclude by discussing the various channels that likely affect private plans' cost-sharing decisions.
我们探讨了私人药品计划在医疗保险D部分的背景下如何设定费用分摊。虽然公共提供的药品覆盖范围通常涉及各类药品统一的费用分摊,但我们记录了私人提供的计划中不同药品费用分摊存在的显著异质性。我们还记录到,私人计划系统性地为需求弹性较大的药品或类别设定了更高的消费者费用分摊;为此,我们估计了150多种药品和100多个治疗类别的需求价格弹性。最后,我们讨论了可能影响私人计划费用分摊决策的各种渠道。